Despite cash requirements for transaction and integration costs of approx. € 4m resulting from the acquisition, Evotec confirms to keep a very strong strategic cash balance also in 2011. For the current fiscal year, the Company expects to grow revenues by more than 15% and to end the year 2011 with a liquidity of more than € 64 m.

Evotec invites you to join a conference call announcing the acquisition of Kinaxo.

Details of the Conference Call:
Thursday 10 February 2011 at 
8.30 a.m. CET 
7.30 a.m. GMT/2.30 a.m. US Time (East Coast) 

Dial-in Numbers:
Europe: 
+49 (0) 6958 999 0805 (Germany) 
+44 (0) 207 153 2027 (UK) 
US: +1 480 629 9724
 
Pass Code: 4407349 

A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com , password: evotec0211.

You can also listen to the conference call via audio webcast including presentation slides at www.evotec.com.

If you are unable to attend, a recording will be available for 24 hours after the call at the following phone numbers: +49 (0) 69 58 99 90 568 (Germany), +44 (0) 20 7959 6720 (UK), +1 303 590 3030 (US). The access code is 4407349#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors/Events/Financial Calendar.

ABOUT EVOTEC AG

Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression and an alliance in the field of diabetes with Andromeda (Teva). For additional information please go to www.evotec.com.

ABOUT KINAXO

Kinaxo is a privately held biotechnology company based in Munich, Germany. The company was founded in 2005 and currently employs 25 employees. Following the transaction, Kinaxo will be fully integrated into Evotec's operations.